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ABSTRACT
OBJECTIVE
To assess the performance of the SARS-CoV-2 antigen 
rapid lateral flow test (LFT) versus polymerase 
chain reaction testing in the asymptomatic general 




Community LFT pilot at covid-19 testing sites in 
Liverpool, UK.
PARTICIPANTS
5869 asymptomatic adults (≥18 years) voluntarily 
attending one of 48 testing sites during 6-29 
November 2020.
INTERVENTIONS
Participants were tested using both an Innova LFT and 
a quantitative reverse-transcriptase polymerase chain 
reaction (RT-qPCR) test based on supervised self-
administered swabbing at testing sites.
MAIN OUTCOME MEASURES
Sensitivity, specificity, and predictive values of LFT 
compared with RT-qPCR in an epidemic steady state of 
covid-19 among adults with no classic symptoms of 
the disease.
RESULTS
Of 5869 test results, 22 (0.4%) LFT results and 343 
(5.8%) RT-qPCR results were void (that is, when 
the control line fails to appear within 30 minutes). 
Excluding the void results, the LFT versus RT-qPCR 
showed a sensitivity of 40.0% (95% confidence 
interval 28.5% to 52.4%; 28/70), specificity of 99.9% 
(99.8% to 99.99%; 5431/5434), positive predictive 
value of 90.3% (74.2% to 98.0%; 28/31), and 
negative predictive value of 99.2% (99.0% to 99.4%; 
5431/5473). When the void samples were assumed 
to be negative, a sensitivity was observed for LFT of 
37.8% (26.8% to 49.9%; 28/74), specificity of 99.6% 
(99.4% to 99.8%; 5431/5452), positive predictive 
value of 84.8% (68.1% to 94.9%; 28/33), and 
negative predictive value of 93.4% (92.7% to 94.0%; 
5431/5814). The sensitivity in participants with an 
RT-qPCR cycle threshold (Ct) of <18.3 (approximate 
viral loads >106 RNA copies/mL) was 90.9% (58.7% 
to 99.8%; 10/11), a Ct of <24.4 (>104 RNA copies/
mL) was 69.4% (51.9% to 83.7%; 25/36), and a Ct 
of >24.4 (<104 RNA copies/mL) was 9.7% (1.9% to 
23.7%; 3/34). LFT is likely to detect at least three 
fifths and at most 998 in every 1000 people with a 
positive RT-qPCR test result with high viral load.
CONCLUSIONS
The Innova LFT can be useful for identifying infections 
among adults who report no symptoms of covid-19, 
particularly those with high viral load who are more 
likely to infect others. The number of asymptomatic 
adults with lower Ct (indicating higher viral load) 
missed by LFT, although small, should be considered 
when using single LFT in high consequence settings. 
Clear and accurate communication with the public 
about how to interpret test results is important, given 
the chance of missing some cases, even at high viral 
loads. Further research is needed to understand 
how infectiousness is reflected in the viral antigen 
shedding detected by LFT versus the viral loads 
approximated by RT-qPCR.
Introduction
The global SARS-CoV-2 pandemic has been responsible 
for many deaths and has had a profound, enduring 
effect on the livelihoods and life chances of people 
worldwide. Identifying those with covid-19 has become 
a key strategy for limiting the spread of the disease, 
with quantitative reverse-transcriptase polymerase 
chain reaction (RT-qPCR) testing being used as the 
reference standard in the diagnosis of covid-19. In a 
public health rather than clinical context, however, 
the hours or days taken to receive a RT-qPCR test result 
is time when infected people might be transmitting 
the virus to others. The cost and capacity of RT-qPCR 
testing also limit its value for public health uses. As a 
consequence, low cost, rapid lateral flow technology 
(LFT), such as that used in pregnancy test kits, was 
developed to detect the nucleocapsid protein antigen 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
The Innova SARS-CoV-2 antigen rapid lateral flow test (LFT) was adopted for large 
scale UK pilots of community testing in response to covid-19, including open 
access testing for asymptomatic residents of Liverpool, UK
Although the evaluation of the test’s accuracy in people with symptoms is well 
documented, limited data are available for its use in asymptomatic people
WHAT THIS STUDY ADDS
Innova LFT results were positive for most people with high viral load (likely to be 
infectious) who tested positive using reverse-transcriptase polymerase chain 
reaction (RT-qPCR), whereas results were negative for most people with viral load 
<104 RNA copies/mL (expected to be less infectious)
Policy makers need to consider LFT utility in context sensitive ways, regarding 
population levels of infection, phases of epidemic curves, and the transmission 
risks and consequences in specific settings
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of SARS-CoV-2, the virus responsible for covid-19.1 
The LFT provides results within 30 minutes and can be 
carried out without the need for a laboratory, offering 
the potential to rapidly identify people with covid-19, 
ideally leading to quick isolation, and breaking 
transmission chains.
The Innova LFT was adopted for large scale English 
pilots of community testing in response to covid-19, 
including open access testing for asymptomatic 
residents of Liverpool in England. An initial 
evaluation, undertaken as part of the test development 
and evaluation programme commissioned by the 
Department of Health and Social Care, and conducted 
by Public Health England Porton Down laboratory 
and the University of Oxford, reported test sensitivity 
compared with RT-qPCR of 79% when the LFT was 
read by laboratory scientists, 73% when read by 
trained healthcare workers, and 58% when read by 
self-trained staff members at a test and trace centre.2 
The study considered both people with and without 
symptoms and found no evidence of a difference in 
sensitivity. However, the study participants were part 
of a testing service for people with symptoms and 
details are lacking as to why asymptomatic people 
were tested. A recent review suggested that LFT can 
be less accurate in asymptomatic people than in those 
with symptoms.3
We assessed the performance of LFT to detect current 
SARS-CoV-2 infection in the general population 
without symptoms attending covid-19 testing centres. 
The use of RT-qPCR as the reference standard test is, 
however, questionable because RT-qPCR can detect 
SARS-Cov-2 for an average of 17 days, and often for 
longer. For much of this period, the individual is likely 
to have stopped being infectious.4-6 The RT-qPCR cycle 
threshold (Ct) offers an indication of viral load, which 
is understood to be linked to the level of infectiousness 
of someone with covid-19. Nevertheless, the precise 
relation in any individual between Ct and viral load, 
and between viral load and infectiousness is still 
unclear.7 8 The PHE evaluation2 indicated that LFT 
was able to identify more than 90% of people with a 
Ct <25, corresponding approximately to a viral load of 
>105 RNA copies/mL, indicating that the LFT has the 
potential to identify most of those who are infectious. 
Some concerns remain about the use of LFT, however, 
most noticeably about the accuracy reported by self-
trained or non-expert readers in the asymptomatic 
population.9
On 6 November 2020 a community testing 
programme, piloted in Liverpool and sponsored by 
the Department of Health and Social Care, started with 
the aim of identifying more infected people earlier 
in their infection cycle so they could self-isolate and 
break transmission chains. To assess the performance 
and appropriate implementation of the Innova LFT in 
Liverpool, we performed a quality assurance exercise. 
We compared the sensitivity, specificity, and predictive 
values of the LFT with a RT-qPCR test sampled within 
minutes of self-administered swabbing by the same 
individual at the testing site. The sensitivity of the 
LFT as a function of PCR Ct (viral load proxy) was also 
investigated.
Some initial results from this Liverpool pilot have 
been reported previously10 11 and have been debated in 
the literature,12-19 but to date have not been published 
in the peer reviewed literature. We report the quality 
assurance findings of that study.
Methods
Study design and participants
Asymptomatic people attending testing sites in 
Liverpool between 8 and 29 November 2020 were 
invited to participate in this prospective quality 
assurance exercise. Eligible participants were 
adults (≥18 years) who did not display any of the UK 
government’s list of symptoms for covid-19 (new 
continuous cough, high temperature, or loss of, or 
change in, normal sense of taste or smell). Participants 
provided verbal consent (recorded) to take part. 
Recruitment rotated between 48 test sites until the 
team had either recruited 200 participants at a site, or 
two days of recruitment at that site had elapsed without 
the target being reached. Reasons for not being invited 
to participate were age younger than 18 years old or 
the volume of people at a test centre prohibited this 
additional recruitment step. Otherwise all individuals 
consecutively attending the relevant test centres were 
invited to participate.
Sample size was predefined by NHS Test and Trace 
service at 200 in each testing site and not based on 
statistical calculations from the evaluation team. 
This balance was pragmatic to account for potential 
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variability across sites (eg, differences in personal 
and socioeconomic characteristics). Similar numbers 
of participants (n=200) were recruited in each site. 
Assuming about a 1% prevalence for covid-19, the 
sample size was anticipated to provide on average 
one or two positive test results in each test site. 
Participants received both an Innova LFT and an RT-
qPCR test to be self-administered swabs (combined 
throat and nose) under supervision and taken at the 
same appointment within minutes. The LFT test was 
always taken first and graded within 30 minutes. 
Trained observers monitored this process to ensure 
that the manufacturer’s instructions were followed. 
The site team analysed the LFT directly according to 
the Department of Health and Social Care standard 
protocol, with the result confirmed by the quality 
assurance team. The team were members of the armed 
forces who were provided with a set of standard 
operating instructions, detailing how to process the 
swab sample and how to interpret the results. The same 
version of the Innova LFT (product code BT1309) was 
used for the city-wide testing pilot. The second swab 
was sent for RT-qPCR analysis at one of the Lighthouse 
laboratories using its standard RT-qPCR SARS-CoV-2 
assay (TaqPath; ThermoFisher Scientific). Neither test 
result was graded with knowledge of the other test 
result. The results were sent from NHS Test and Trace to 
Liverpool’s integrated health and social care and public 
health data system (www.cipha.nhs.uk) and analysed 
by an independent team at the University of Liverpool. 
The supplementary file provides further information 
on the quality assurance protocol developed by the 
Department of Health and Social Care.
Ct values and connection with viral load
Ct is defined as the number of cycles required for the 
sample fluorescence in the laboratory to exceed a 
chosen threshold for positivity. Ct values provide an 
indication of the concentration of viral RNA in a sample 
tested by the RT-qPCR method, such that low Ct values 
tend to be linked to high viral loads and, conversely, 
high Ct values tend to be linked to low viral loads. 
Lack of standardisation of Ct values across different 
laboratories and equipment makes it challenging to 
compare Ct values between studies using difference 
laboratories. The RT-qPCR test used here corresponds 
to the standard test used in UK Lighthouse laboratories 
studies, and we have used the same Ct thresholds to 
calculate sensitivity of LFT compared with RT-qPCR 
to allow easy comparison.8 Our study protocol had no 
prespecified Ct cut-offs. Ct values were converted into 
approximate viral loads using the calibration curve 
performed for the Glasgow laboratory (log10(viral 
load)=12−0.328×Ct), since it is understood to be 
generalisable to other Lighthouse laboratories using 
similar methods.8
Statistical analysis
We used the Clopper-Pearson exact method to estimate 
the sensitivity, specificity, positive predictive value, and 
negative predictive values along with corresponding 
95% confidence intervals. For the purposes of this 
analysis, we regarded RT-qPCR as the reference 
standard, although we acknowledge that viral 
shedding (reflected by LFT) and viral loads (reflected 
by RT-qPCR Ct) are temporally aligned processes. 
Estimates of sensitivity were provided for each Ct 
interval, which we calculated as the combined average 
of existing genes (such that if a particular gene had 
a missing value, the average was calculated over the 
remaining Ct scores). Void results were not included in 
calculation of accuracy variables for the main analysis. 
However, for completeness, we also assessed accuracy 
taking into account void results (for either test) by 
grouping them with the negative results.20 A voided 
RT-qPCR test is one that is either operationally non-
analysable (eg, insufficient sample for analysis) or has 
an analytically inconclusive fluorescence amplification 
curve. In some of these cases amplification might have 
been observed for one of the target genes, but this was 
determined to be based on either background signal 
or sample contamination. A voided LFT test result is 
one where the control line fails to appear within 30 
minutes. Estimates of sensitivity were also generated 
based on the N gene (the nucleocapsid antigen that 
LFT is designed to detect) as well as based on the S 
(spike protein) gene and ORF1ab (open reading frame 
1ab) for completeness.
When multiple LFT and RT-qPCR tests were 
identified from the same participant, we included only 
one pair of test results in the main analysis following 
predefined selection criteria (see supplementary 
file). Sensitivity analyses were performed to consider 
scenarios where agreement between LFT and RT-
qPCR results was maximised and minimised based 
on the results from multiple tests for each individual. 
An additional analysis including all multiple tests 
(assuming independence) was also conducted. 
Statistical analyses were carried out in R (version 3.6.1 
or later) and checked by a second statistician using 
SAS software (version 9.4).
Patient and public involvement
This study uses data from Liverpool’s integrated health 
and social care and public health data system, and it 
is an urgent public health research study in response 
to a public health emergency of international concern. 
Patients and the public were not involved in the design, 
conduct, or reporting of the study.
Results
Personal characteristics of the participants were not 
collected as part of this quality assurance study. It was, 
however, possible to use the Combined Intelligence for 
Population Health Action platform to access results 
for all but 116 of the LFT tests conducted in the study 
to extract basic personal information. The mean age 
of the participants was 50 years (SD 18 years), 54% 
were women, and most were of white ethnicity (82%). 
Supplementary table S4 and figures S1-S4 provide 
additional information on the characteristics of the 
study cohort, flowchart, distribution of the number of 
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tests by test centre, and test results over time. Personal 
characteristics were similar between the study 
participants and those who attended the test centres 
on the same day as the study team (supplementary 
table S5).
Forty participants had taken part in the study on 
more than one occasion—30 had the same LFT and 
RT-qPCR paired results and 10 showed inconsistent 
results for LFT or RT-qPCR, or both (see supplementary 
file).
Overall, 5869 asymptomatic adults from 48 testing 
sites in Liverpool participated in this study. Table 1 
shows the results for pairs of LFT and RT-qPCR tests 
for each participant. After excluding void test results, 
the sensitivity was found to be 40.0% (95% confidence 
interval 28.5% to 52.4%; 28/70), specificity 99.9% 
(99.8% to 99.99%; 5431/5434), positive predictive 
value 90.3% (74.2% to 98.0%; 28/31), and negative 
predictive value 99.2% (99.0% to 99.4%; 5431/5473). 
Positive and negative predictive values were directly 
estimated from the data, which showed a 1.3% 
prevalence; the Office for National Statistics reported 
a prevalence of 2.3% for West Lancashire, Liverpool, 
Knowsley, and Sefton on 20 November.21 The lower 
percentage of positive test results in the current study 
reflects that all testing was conducted in people 
without covid-19 symptoms.
When the void results for either test were grouped 
with the negative results, a sensitivity was observed 
for LFT of 37.8% (26.8% to 49.9%; 28/74), specificity 
of 99.6% (99.4% to 99.8%; 5431/5452), positive 
predictive value of 84.8% (68.1% to 94.9%; 28/33), 
and negative predictive value of 93.4% (92.7% to 
94.0%; 5431/5814). Including void results in this way 
provides a more conservative estimate of sensitivity, 
given that void LFT results linked to a positive PCR 
result are assumed to be negative.20
Figure 1 and table 2 present the results for sensitivity 
of the LFT against RT-qPCR by viral load. In the context 
of a positive RT-qPCR test result with high viral load 
(>106 RNA copies/mL) the LFT was able to detect 
90.9% (58.7% to 99.8%; 10/11) of cases. The LFT 
detection rate of participants with a positive RT-qPCR 
result decreased substantially as viral load decreased. 
For example, for those with a viral load <104 RNA 
copies/mL the sensitivity was only 9.7% (1.9% to 
23.7%; 3/34). Figure 2 shows LFT sensitivity against 
mean Ct value.
The LFT results assessed on site showed a high level 
of concordance (99.9%) with the quality assurance 
team’s readings, with 5845 concordant and two 
discordant samples (99.9% concordance, excluding 
voids, almost identical if voids are included; see 
supplementary table S2). Interobserver agreement did 
not differ noticeably across test sites.
Two additional analyses based on agreement or 
disagreement between LFT and RT-qPCR test results 
for those participants with multiple tests showed 
that the selection criteria followed had a minor effect 
on the accuracy variables (see supplementary table 
S3). Results remained similar when multiple tests 
were included (ie, treating multiple pairs of tests for 
the same individuals as if they were independent 
observations; supplementary table S4).
Discussion
We report a city-scale evaluation of Innova LFT 
versus RT-qPCR test results among the general 
population attending asymptomatic testing centres 
voluntarily in Liverpool between 8 and 29 November 
2020. Participants declared that they did not have 
classic symptoms of covid-19 and we have drawn no 
conclusions about those who may have been (pre-; 
pauci-) symptomatic. The sample was representative 
of those attending asymptomatic testing centres 
concurrently (supplementary table S5). Contrasts with 
the wider population have been described elsewhere.22
The overall sensitivity of the Innova LFT was 
40%—a potentially misleading statistic if RT-qPCR 
detects a large proportion of people post-infection.18 
RT-qPCR is exquisitely sensitive for detecting SARS-
CoV-2 RNA in those with replicating virus or those 
whose immune systems have controlled the infection 
and are less likely to be infectious. So a substantial 
proportion (depending on the epidemic phase) of 
people with a positive RT-qPCR test result will no 
longer be infectious.5 7 In our study, LFT achieved 90% 
sensitivity compared with people found to be positive 
by RT-qPCR testing with a high viral load >106 RNA 
copies/mL, and the corresponding 95% confidence 
interval indicated that LFT is likely to detect at least 
three fifths and at most 998 in every 1000 people with 
a positive RT-qPCR test result with high viral load. 
For comparison, LFT achieved a sensitivity of 72.4% 
(52.8% to 87.3%) in those with an approximate viral 
load >105 RNA copies/mL.
Comparison with other studies
Other rapid antigen tests have been assessed for their 
ability to detect people with confirmed covid-19 by RT-
Table 1 | Results of rapid lateral flow test (LFT) and quantitative reverse-transcriptase polymerase chain reaction  
(RT-qPCR) tests in quality assurance dataset (5869 participants)
LFT result
RT-qPCR result
Predictive valuesPositive Negative Void Total (%)
Positive 28 3 2 33 (0.6) 90.3 (74.2 to 98.0)
Negative 42 5431 341 5814 (99.1) 99.2 (99.0 to 99.4)
Void 4 18 0 22 (0.4)
Total (%) 74 (1.3) 5452 (92.9) 343 (5.8) 5869
Sensitivity (%, 95% CI) 40.0 (28.5 to 52.4)
Specificity (%, 95% CI) 99.9 (99.8 to 99.99)
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qPCR testing, reporting broadly similar sensitivity and 
specificity in asymptomatic people as we report for the 
Innova LFT in the Liverpool pilot.23-25 All three studies 
also report similar ability to detect lower Ct values with 
higher sensitivity. Although our study involved mainly 
white British people, comparable results have been 
recorded in other countries and ethnic groups.26 27
The association between covid-19 viral load and 
infectiousness has not yet been fully characterised.8 28 
Analysis of NHS Test and Trace contact data suggests 
that a lower Ct in the index case (ie, higher viral load) 
increases the likelihood of contacts testing positive for 
covid-19.8 This study traced 64% of all contacts and 
observed that 13% of case-contact pairs with a contact 
who tested positive by RT-qPCR had case viral loads 
<104 RNA copies/mL, 40% of case-contact pairs had 
case viral loads between 104 and 106 RNA copies/mL, 
and around 47% of case-contact pairs with contacts 
who tested positive by RT-qPCR- had case viral loads 
>106 RNA copies/mL. A recent Spanish contact tracing 
study28 identified that more than 85% of transmission 
events occurred in clusters linked to an index case 
with a viral load of >105 RNA copies/mL. These studies 
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Fig 1 | Number of participants with negative and positive lateral flow test (LFT) results 
by quantitative reverse-transcriptase polymerase chain reaction (RT-qPCR) viral load 
(based on mean cycle threshold (Ct) score across three gene targets). Intervals show 
the 95% confidence interval for the cumulative sensitivity to detect viral loads >1, >102, 
>104, and >106 RNA copies/mL
Table 2 | Results of rapid lateral flow test (LFT) with a breakdown by cycle threshold (Ct) value
RT-qPCR test (mean across three gene targets)
Ct (RNA copies/mL) Void tests with Ct value







 Negative 1 10 14 17 5 8 328 5431
 Positive 10 15 3 0 0 0 2 3
 Void 0 4 0 0 0 0 0 18
Sensitivity (%, 95% CI) 90.9 (58.7 to 99.8) 60.0 (38.7 to 78.9) 17.6 (3.8 to 43.4) 0.0 (0.0 to 19.5)
Cumulative sensitivity‡ 
(%, 95% CI) 90.9 (58.7 to 99.8) 69.4 (51.9 to 83.7) 52.8 (38.6 to 66.7) 40.0 (28.5 to 52.4)
N gene
LFT site results:
 Negative 1 8 16 15 2 6 4 331 5431
 Positive 7 17 3 1 0 0 0 2 3
 Void 0 4 0 0 0 0 0 0 18
Sensitivity (%, 95% CI) 87.5 (47.3 to 99.7) 68.0 (46.5 to 85.1) 15.8 (3.4 to 39.6) 6.3 (0.1 to 30.2)
Cumulative sensitivity‡ 
(%, 95% CI) 87.5 (47.3 to 99.7) 72.7 (54.5 to 86.7) 51.9 (37.6 to 66.0) 41.2 (29.4 to 53.8)
S gene
LFT site results:
 Negative 1 10 13 9 9 1 4 336 5431
 Positive 10 15 3 0 0 0 2 3
 Void 0 4 0 0 0 0 0 18
Sensitivity (%, 95% CI) 90.9 (58.7 to 99.8) 60.0 (38.6 to 78.9) 18.8 (4.0 to 45.6) 0.0 (0.0 to 33.6)
Cumulative sensitivity‡ 
(95% CI) 90.9 (58.7 to 99.8) 69.4 (52.9 to 83.7) 53.8 (39.5 to 67.8) 45.9 (33.1t o 59.2)
ORF1ab gene
LFT site results:
 Negative 3 10 13 8 7 1 2 338 5431
 Positive 12 14 2 0 0 0 0 2 3
 Void 1 3 0 0 0 0 0 0 18
Sensitivity (%, 95% CI) 80.0 (51.9 to 95.7) 58.3 (36.6 to 77.9) 13.3 (1.7 to 40.5) 0.0 (0.0 to 36.9)
Cumulative sensitivity‡ 
(%, 95% CI) 80.0 (51.9 to 95.7) 66.7 (49.8 to 80.9) 51.9 (37.8 to 65.7) 45.2 (32.5 to 58.3)
RT-qPCR=quantitative reverse-transcriptase polymerase chain reaction; NA=not applicable (missing gene target).
*Implies PCR result was graded as positive but particular target gene was not detected for that sample.
†When void PCR results were returned, Ct value was observed for at least one target gene in a small number of participants, but this was determined to be inconclusive.
‡Defined using number of samples with Ct less than upper threshold.
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higher chance of infecting others, but they also show 
that transmission of covid-19 can occur in those with 
low viral load. It is nevertheless possible that some 
of these instances of transmission were confounded 
by third party transmission, or that the transmission 
occurred when the individual’s viral load was much 
higher. However, the evidence gathered to date suggest 
that people with a low viral load (about ≤105 RNA 
copies/mL) could still be infectious, although the 
chance of infecting others is lower than for those with a 
higher viral load. Although our study, conducted in an 
asymptomatic population, shows that LFT can detect 
most people with a high viral load, and therefore those 
at a higher risk of transmitting SARS-CoV-2, the LFT 
missed 10% of people with a high viral load >106 RNA 
copies/mL, 30% of cases with a viral load >104 RNA 
copies/mL, and most of the cases with a viral load <104 
RNA copies/mL who might have contributed to virus 
transmission.8 This suggests that care is needed when 
conveying negative LFT results so as not to give false 
reassurance.15 Both of these contact tracing studies 
were in people with symptoms, who generally had 
higher viral loads than observed in our study. Contact 
tracing studies are currently the best instruments we 
have of transmission in whole populations. However, 
contact tracing systems evolve over time, and selection 
biases might be present related both to the recall of the 
original case and to the response of the contacts. In 
addition, these studies provide a snapshot of people at 
the point of PCR testing, so do not necessarily reflect 
the interaction between people or the progression 
of the virus in people before being tested. For these 
reasons caution is needed in using contact tracing 
studies to infer the proportion of infectious people 
detected by LFT.
Limitations of this study
A technical limitation is that RT-qPCR targeting the N 
gene might detect fragments of RNA and hence could 
overestimate the number of viral copies in a sample. 
The ORF1ab gene is only detected on viral genomic 
RNA and might be a better estimate of the actual 
number of genome copies per millilitre.29 In our study 
we found an insubstantial reduction in sensitivity for 
detecting high viral loads when only the ORF1ab cycle 
thresholds were considered (table 2).
Although RT-qPCR tests can detect small amounts 
of RNA, sensitivity can be affected by swabbing 
technique and by substantial and largely unexplained 
heterogeneity between studies in sensitivity to detect 
SARS-Cov-2 positivity in people who might have 
tested positive with a different swab sample. A recent 
systematic review identified 34 studies with RT-qPCR 
false negative rates (1−negative predictive value) 
ranging from 2% to 58%.30 The sensitivity of the LFT is 
also substantially affected by the quality of the sample 
and swabbing technique.2 31 32 The LFT was always 
done first. In theory this could have depleted the 
source material and hence virus nucleic acid available 
for the subsequent swab for RT-qPCR testing, although 
it is also possible that the second swab benefited from 
a training effect. In addition, variation in LFT device 
build quality, lack of quality assurance certification by 
batch of test, and storage temperatures are additional 
sources of heterogeneity that are poorly recorded.10 
The instructions for use of the LFT state that the tests 
should be stored between 2°C and 30°C and used at 
room temperature of between 15°C and 30°C. Given 
the relatively mild autumn temperatures in the UK, 
ambient storage conditions should have remained 
within these ranges and therefore we do not anticipate 
this had an impact on the performance of the LFTs.
Conclusions
Our study suggests that the LFT can be a useful tool 
among wider public health measures for the control 
of SARS-CoV-2 transmission and to mitigate risk 
of covid-19. The predictive value of testing, and in 
particular of LFT, varies with the phase of the epidemic 
curve and the population prevalence of infection,33 
which was declining at the time of this quality 
assurance study in Liverpool.18 Our study also shows 
that about one 10th of the people with higher viral 
load (>106 RNA copies/mL) detected by RT-qPCR are 
missed, which highlights the need to assess the impact 
that false negative test results might have in specific 
contexts. Some false negative LFT results occur at a 
time when an individual’s viral load is declining, and 
therefore they might no longer be highly infectious. A 
proportion of false negative LFT results are expected 
to correspond to the early phase of the infectious 
trajectory, when viral load might increase in the next 
48 hours. For such individuals, serial testing could 
improve sensitivity, and optimal testing regimens 
need further study. Although false negative results 
might reflect those who are no longer infectious, there 
is a risk of false reassurance leading to behaviours 
that increase transmission. Careful communication 
is needed around all negative test results, and 
symptomatic people should continue to be encouraged 
to attend for PCR testing, allowing LFT to be seen to be 
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Fig 2 | Cumulative sensitivity of Innova lateral flow test (LFT) against quantitative 
reverse-transcriptase polymerase chain reaction (RT-qPCR) cycle threshold (Ct). Dashed 
orange lines show approximate viral loads (RNA copies/mL)
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The Innova LFT seems, in combination with other 
health protection measures, to be a valuable tool 
in wider public health responses to covid-19 for 
identifying those with higher viral loads who are 
more likely to be infectious but do not report classic 
symptoms. To maximise the value of LFT, care should 
be taken to train test operatives, communicate the 
meaning of results to tested people, target testing with 
reference to background case rates, and avoid single 
LFT results for access to vulnerable settings (such as 
care homes) where the consequences of infection are 
severe (unless comprehensive additional risk reduction 
measures are considered). Further studies are needed 
to understand the relation between LFT results and 
infectiousness.
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